SCHEMBL6795495

SCHEMBL6795495

CCCCn1c(=O)n(OCc2ccccc2)c(=O)c2cc(F)c(Cl)nc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.41
ADORA2A P29274 3/20 0.39
ADORA1 P30542 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
ADORA2B P29275 1/20 0.38
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
TSHR P16473 4/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6796950 0.90 ALDH1A1 (0.40) ADORA1ALDH1A1L3MBTL1TDP1TSHR
SCHEMBL6801045 0.88 MAPT (0.41) ADORA3ADORA2AALDH1A1HTTSMN1; SMN2
SCHEMBL6798888 0.84 MEN1 (0.38) ADORA3ADORA2AADORA1ALDH1A1HTT
SCHEMBL6795249 0.80 PDE4A (0.41) ALDH1A1SMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL6801352 0.78 ALDH1A1 (0.39) ALDH1A1HTTSMN1; SMN2KDM4EMEN1
SCHEMBL6798905 0.78 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL6797355 0.77 ALDH1A1 (0.43) ADORA3ALDH1A1HTTSMN1; SMN2MEN1
SCHEMBL6797211 0.77 GLA (0.42) ALDH1A1HTTSMN1; SMN2MEN1KMT2A
SCHEMBL6799493 0.75 PPARD (0.35) ALDH1A1MEN1KMT2AL3MBTL1TSHR
SCHEMBL6799891 0.74 HRH4 (0.40) ALDH1A1KMT2AL3MBTL1TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US claimed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP claimed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US claimed
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A ADORA3 3304/4885ADORA2A 3752/4885ADORA1 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.